A recent report published by Infinium Global Research on anti-obesity prescription drugs market provides in-depth analysis of segments and sub-segments in global as well as regional anti-obesity prescription drugs market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional anti-obesity prescription drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global anti-obesity prescription drugs market. According to the report the global anti-obesity prescription drugs market was worth USD 348 million in 2016 and it is projected to reach USD 1095 million by 2024, growing at a CAGR of 4.97% over the forecast period of 2018-2024.
The pharmacological agents that help to reduce or control weight. Anti-obesity drugs help in reducing body mass either by reducing the hunger or increasing the consumption of calories. The ingesting of unhealthy food which is rich in cholesterol has increased which leads to a rise in demand for anti-obesity prescription drugs. The rising level of chronic stress also contributes to obesity. Rising consumption of alcoholic beverages and unhealthy food which is rich in cholesterol that leads to obesity is driving the growth of the market. Growing occurrence of depression has led to growing consumption of the psychotropic drugs; the side effect of this drug is increasing which result in obesity. Moreover, increasing incidences of diabetes have surged up the consumption of medications. These medications have appetite stimulating features, due to which the patients incline to eat more. Eating disorders due to antidepressants and diabetic drugs increase the diet which has sustained to contribute towards obesity. Growing demand for obesity management is expected to impact the growth of the global anti-obesity prescription drugs market positively.
The report on global anti-obesity prescription drugs market covers segments such as drug class, distribution channel and age group. On the basis of drug class, the global anti-obesity prescription drugs market is categorized into orlistat, phentermine, and topiramate, bupropion, and naltrexone, lorcaserin and liraglutide. On the basis of distribution channel the global anti-obesity prescription drugs market is categorized into retail pharmacy, hospital pharmacy, and online pharmacy. On the basis of age group the global anti-obesity prescription drugs market is categorized into pediatric and adult.
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this section, the key trends and market size for each geography is provided over the period of 2016-2024. The countries covered in the North America region include the U.S., Canada, and Mexico; while Asia-Pacific includes China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are included in the European region. The U.S. drives the growth in the North America region as it is the largest market in the region. The Asia-pacific region offers a substantial potential for the market growth owing to rapid growth in markets such as India and China. Countries such as the U.S., the U.K., and France among others has reported a substantial rise in the obesity population. Moreover, growing work stress in emerging markets of Asia-pacific is likely to cause rise in obesity cases in the years to come over the next six years. According to the study, North America followed by Europe accounted for the largest market share in the word anti-obesity prescription drugs market in 2016 and this trend is projected to continue over the forecast period, with increasing awareness among the people in the U.S. and Canada.
The report provides profiles of the companies in the global anti-obesity prescription drugs market such as F Hoffmann La Roche Ltd, Orexigen Therapeutics, Inc, Novo Nordisk A/S, Arena Pharmaceuticals, Inc, GlaxoSmithKline, VIVUS, Inc, Boehringer Ingelheim, Alizyme and Others. Recently approved Saxenda by Novo Nordisk is growing at a fast growth rate due to rising interest among obese people.Novo Nordisk, an innovator of drugs in the obesity market introduces Saxenda in all the major markets with a higher dose of glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, This Dual therapy can be used for both obesity and type 2 diabetes is the latest trend in the market.
The report provides deep insights on demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the global anti-obesity prescription drugs market. Moreover, IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of anti-obesity prescription drugs market. Moreover, the study highlights current market trends and provides forecast from 2018-2024. We also have highlighted future trends in the anti-obesity prescription drugs market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players. This report will help manufacturers, suppliers, and distributors of the anti-obesity prescription drugs market to understand the present and future trends in this market and formulate their strategies accordingly.
Get free analyst support for the queries before and post purchasing report.
Be assured of 100% customer satisfaction about the research and get 24X7 customer support.
Infinium has achieved over 400%+ growth in its repository and revenue over the last 2 years. Yes, we are proud to say we are growing at a great pace and becoming a trusted partner among our clients.
sign up for our newsletter